Insulet (NASDAQ:PODD) Stock Price Target Raised at Barclays

Insulet (NASDAQ:PODD) had its price objective hoisted by Barclays from $150.00 to $165.00 in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has an equal weight rating on the medical instruments supplier’s stock.

A number of other research firms have also commented on PODD. Jefferies Financial Group reissued a “buy” rating and issued a $200.00 price objective on shares of Insulet in a research note on Wednesday. Truist Financial lowered Insulet from a “buy” rating to a “hold” rating and lowered their target price for the company from $210.00 to $153.00 in a research note on Wednesday, August 5th. UBS Group lifted their price target on Insulet from $150.00 to $171.00 and gave the company a “neutral” rating in a report on Thursday. Oppenheimer downgraded shares of Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, Robert W. Baird set a $175.00 target price on shares of Insulet in a research report on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $185.38.

Insulet Price Performance

PODD stock traded down $9.61 during trading on Friday, hitting $146.51. 1,567,721 shares of the stock traded hands, compared to its average volume of 1,380,594. Insulet has a one year low of $126.40 and a one year high of $354.88. The stock has a market cap of $10.16 billion, a price-to-earnings ratio of 23.86, a P/E/G ratio of 1.21 and a beta of 1.06. The company has a 50 day simple moving average of $141.97 and a 200 day simple moving average of $176.65. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.59 by $0.40. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company’s quarterly revenue was up 19.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.24 earnings per share. Equities analysts expect that Insulet will post 6.75 EPS for the current fiscal year.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. Elevation Wealth Partners LLC lifted its position in Insulet by 115.6% during the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 104 shares during the period. Activest Wealth Management grew its position in shares of Insulet by 186.3% during the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 149 shares during the period. WPG Advisers LLC grew its position in shares of Insulet by 169.3% during the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 171 shares during the period. Covestor Ltd raised its stake in shares of Insulet by 103.9% during the third quarter. Covestor Ltd now owns 310 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 158 shares during the last quarter. Finally, Jacobi Capital Management LLC bought a new stake in shares of Insulet during the third quarter worth approximately $40,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.